Aisheng Biotech Completes Angel Round Led by Daotong Investment to Accelerate Clinical Trials of Small-Diameter Artificial Blood Vessels

VCBeat learned that recently, AERSUN announced the completion of its angel round of financing, which was exclusively invested by Dalton Venture. The funds raised will be mainly used for the clinical advancement of small-caliber artificial blood vessels and the development of extended applications of core technologies.

AERSUN, incubated from Hubei Zhongchuang Medical Supplies Co., Ltd., was established as an independent company in 2023. As a professional R&D and manufacturing enterprise in the field of tissue repair and reconstruction, the company focuses on the development, production, and sales of high-end implantable medical device products. AERSUN not only has deep cooperation with Wuhan University of Technology but also has established long-term partnerships with clinical medical experts in China. It closely aligns with clinical needs, promotes the integration of medicine and engineering, and connects the industry chain of research, production, academia, and medicine.

Artificial blood vessels refer to prostheses used to replace human blood vessels, create bypass grafts between vessels, or form shunts. Currently, this market is monopolized by imported products over the long term. Small-diameter artificial blood vessels are widely used in clinical applications, but due to limitations of the materials themselves, there are many pain points in their clinical use for scenarios such as vascular access construction for hemodialysis and heart bypass surgeries. Additionally, the prices of imported products are generally very high. Even though hemodialysis has been included in medical insurance, and patients with end-stage renal disease are living longer with a continuously increasing number of hemodialysis patients, the clinical penetration rate of AVG (arteriovenous graft) surgeries in China is far from reaching advanced international levels, indicating that the demand in the market is far from being met.

AERSUN Small-Caliber Artificial Blood Vessels Utilize Unique Technology to Address Clinical Pain Points in Product Development. Currently, A GMP-Level 10,000 Cleanroom, Advanced Laboratories, and Other Facilities Have Been Established at the ZHONGCHUANG Health Industry Park in Jiangxia District, Wuhan, Enabling R&D, Production, and Testing Capabilities While Advancing Clinical Trials for Small-Caliber Artificial Blood Vessels.

Regarding the acquisition of this round of financing,AERSUN Chairman Song Wei said:First of all, we would like to thank Dalton Venture for their recognition and support of our company team and projects. We will adhere to the corporate vision of "becoming an international leader in the field of tissue repair and reconstruction," continue to strengthen cooperation with partners, focus on clinical needs, persist in breakthrough and innovative technical directions, further increase R&D efforts, and launch more competitive products to achieve a win-win situation for doctors, patients, and enterprises, thereby realizing the social value that the company should have.

Mr. Lin Zhencheng, Partner of Dalton Venture, said:Dalton Venture has long been optimistic about the application prospects of bio-regenerative materials in fields such as tissue repair and reconstruction, as well as emergency and critical care. The AERSUN team has completed the development and production process standardization of small-caliber artificial blood vessels, demonstrating unique advantages in long-term patency, repeated puncture resistance, and surgical suturing. At the same time, Mr. Song, as a successful entrepreneur with twenty years of experience in commercialization, operations management, and resource integration, is expected to lead the team to accelerate the productization of domestically produced small-caliber artificial blood vessels, benefiting more hemodialysis patients with improved quality of life.

Dalton Venture focuses on forward-looking medical innovation technologies and is the early exclusive investor in several pioneering technology projects in China. It covers both VC funds and angel funds in the Yangtze River Delta and Greater Bay Area. The core team comes from the healthcare industry, having successfully incubated early-stage startups and established and managed listed companies with a market value of tens of billions. Committed to not only being a value discoverer but also a value creator.

Awarded multiple industry honors such as ChinaVenture VC TOP100, ChinaVenture Medical Device TOP20, Zero2IPO VC TOP100, and Zero2IPO Healthcare TOP30. Partial investment cases: Landing Medical, Hannov Medical, Triastek, Hekin Biotech, Bright Biotech, Shuimu Molecular, Stardust Intelligence, etc.